APLICACIÓN CÉLULAS MADRE

COMO VEMOS HOY EN LAS CELULAS MADRES TENEMOS UNA POSIBLE SOLUCION PARA LA ARTRITIS REUMATOIDEA (AR)

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach. LIPOASPIRATE SOURCE FOR STEM CELL The use of lipoaspirate as a source for stem cells with multipotent differentiation potential offers a far less invasive procedure for cell sampling than the aspiration of bone marrow (BM), and numbers of stem cells obtained are reportedly higher in lipoaspirate than its BM counterpart.1 Lipoaspirate, an otherwise disposible byproduct of cosmetic surgery, has been shown to contain a putative population of stem cells, termed adipose-derived stem cells (ADSCs), that share many similarities to marrow stromal cells (MSCs) from BM, including multilineage differentiation capacity.² Furthermore, these cells also show high colony-forming unit frequencies¹ as well as an apparent pluripotent ability to differentiate to cells of a neuronal phenotype². Finally, the large quantity in which lipoaspirate can be obtained makes it a very attractive alternative source of MSCs for a broad range of research applications